CNTX Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -3.27%, SMA50 23.82%, SMA200 101.29%). The stock’s 14-day RSI is 54.24 (neutral), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -20.0% below its high and over 365.31% above its low. Average 10-day trading volume of 951.66 thousand shares is below the 3-month average of 1.55 million, indicating normal recent market interest.

Context Therapeutics Inc. has 89.70 million shares outstanding. The public float is 37.70 million shares, elevated short interest at 0.71% of float. This equals 521.19 thousand shares. The short ratio is 3.11 days. Institutional investors hold 77.52% of the float. Insiders own 1.45%. Lehr Martin A. holds 920.19 thousand shares, Minai-Azary Jennifer Lynn has 80.01 thousand shares and Levit Alex C. has 29.00 thousand shares.

Context Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.61. This means the shares are trading above this model’s fair value.

Context Therapeutics Inc. generated EPS of -$0.28 over the past year. Five-year average earnings growth is 4.72%. Wall Street analysts project EPS growth of 4.76% annually over the next five years. The latest quarter delivered EPS of -$0.10. The next quarter is forecast at -$0.10. Next year's EPS is expected at $13.16. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $4.00. The high target offers 188.46% upside. The low target suggests 28.21% downside. The mean target is $6.82. This offers 118.59% upside. Context Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 11.11%. The prior quarter beat by 50.0%. Over the last six quarters, Apple has recorded several small beats. These include -50.0% in August 07, 2024.

Context Therapeutics Inc. (NASDAQ:CNTX) closed at $3.12 USD, gaining $0.26 (9.09%) from the previous close of $2.86. The stock is currently mid-range between its 52-week high and low $0.49 and $3.29. With a market capitalization of about $286.66 million, Context Therapeutics Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.97). Key stats such as the average daily volume over the past year has been around 1.54 million shares, trading with heavier-than-usual volume. Headquartered in Philadelphia, PA, Context Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Martin A. Lehr, the company employs approximately 12 people and listed since October 20, 2021. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States.

Context Therapeutics Inc. trades at a P/E ratio of -11.28, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.08 trading at moderately above to book value. The P/FCF stands at -12.86, also below market averages.

Our AI price prediction model suggests that Context Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.64%, with price expected at $3.14 by March 20, 2026, within a range of $2.98 to $3.29 3-Month Outlook: Projected fall of -14.1%, reaching $2.68 by June 04, 2026, with a range of $2.42 to $2.91. 1-Year Outlook: Projected gain of 995.83%, with price at $34.19 by March 05, 2027, within a range of $37.65 to $39.23.

Context Therapeutics Inc. (NASDAQ:CNTX) shares are flat 4.76% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Context Therapeutics Inc. trading at a premium to the broader market with a P/E of -11.28. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.52, suggesting 108.97% upside. Our AI forecast model points to short-term strength (0.64% over two weeks), a medium-term fall (-14.1% over three months), and a longer-term gain (995.83% over one year), with expected trading ranges indicating moderate volatility.